Meds & supplements › Pibrentasvir
Medicine · Hepatitis C Virus NS5A Inhibitor
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
sofidex [Internet]. Daloreum; c2026. Pibrentasvir; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/pibrentasvir
sofidex. (2026, August 3). Pibrentasvir. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/pibrentasvir
Pibrentasvir. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/pibrentasvir
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.